Phillips Stool Softener

Quick links to important sections

Phillips Stool Softener

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Phillips Stool Softener

Quick Facts

Property Description
Active ingredient Docusate sodium (Dioctyl sodium sulfosuccinate or DSS)
Form Capsule, Softgel, Oral liquid (Solution)
Pharmacological class Emollient Laxative (Surfactant Laxative)
Common use Easing stool passage and preventing straining in constipation
Origin Synthetic Anionic Surfactant

What Type of Medicine is Phillips' Stool Softener?

Phillips' Stool Softener is an established over-the-counter preparation classified as an emollient laxative, recognized specifically as a surfactant laxative. This classification identifies the product as a non-stimulant agent that assists the body by gently changing the physical properties of fecal matter, contrasting sharply with products containing strong stimulant laxatives. The efficacy of the Docusate entity is clinically recognized for its accepted role in promoting easier bowel movements across the general population, without provoking direct intestinal muscle contractions. This preparation is often recommended in situations where reduced straining is medically necessary.

Composition, Active Ingredient (Docusate), and Physical Forms

The therapeutic function is dependent upon its sole active ingredient, Docusate sodium, which is a synthetic anionic surfactant—a key differentiating factor from fiber-based laxatives. This substance, chemically known as DSS, is a single-ingredient product administered via the oral route of administration in several practical drug forms, including softgels, capsules, and an oral liquid solution. Phillips' formulation is positioned specifically for effective fecal matter hydration through its surfactant action, as Docusate is widely utilized as a stool softener to treat or prevent constipation.

How a Surfactant Laxative Generally Helps Constipation

The general purpose of this medication is to relieve the difficulty of constipation by promoting softer stool. The Docusate entity performs its physiological action by reducing the surface tension of the stool mass, which allows greater penetration and incorporation of water and lipids. This unique mechanism ensures enhanced fecal matter hydration, which is the core benefit delivered by this class of emollient laxatives.

Regulatory References

  1. NIH LiverTox

What side effects are possible with Phillips Stool Softener?

Possible Side Effects and Safety Information

Adverse reactions associated with docusate sodium (the active ingredient) are classified by regulatory authorities within specific System-Organ Classes, although the frequency is often reported as Not Known or Uncommon in labeling across different regions.

Adverse reaction scope Details from Regulatory Labels
Common Adverse Reactions Nausea, abdominal cramping, and diarrhea are the most frequently listed Gastrointestinal Disorders. Oral liquid formulations may also cause throat irritation.
Serious Adverse Reactions Serious adverse reactions are rare but include severe hypersensitivity reactions (e.g., anaphylaxis) and the potential for severe GI complications, such as rectal bleeding.
Safety-Related Restrictions Official labeling explicitly restricts use when abdominal pain, nausea, or vomiting are present, or when intestinal obstruction is suspected. The product is also restricted from use concurrently with mineral oil due to the risk of increased absorption of the oil.
Duration-Related Patterns Regulatory documents caution that prolonged or excessive use (e.g., beyond seven days) is associated with safety concerns, including the potential for electrolyte imbalance and dependency for bowel function.
Population Considerations Use in the pediatric population (under a specific age, often 2 or 6) is restricted unless directed by a health professional. Safety statements also require professional consultation for use during pregnancy and lactation.

These official safety statements structure the medicine's risk profile by defining the range of possible effects (mostly gastrointestinal), establishing critical boundaries for use with pre-existing symptoms, and outlining the consequences of improper duration of exposure, particularly the risk of electrolyte loss and laxative dependence.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The information provided here is based strictly on authoritative government regulatory warnings regarding Docusate Sodium overdose and mandated emergency actions.

Feature Official Regulatory Statement
Documented Overdose Presentations Gastrointestinal distress, including abdominal cramping, stomach pain, nausea, vomiting, and diarrhea.
Physiological Systems Affected Gastrointestinal system (primary); Fluid and electrolyte balance (secondary serious risk).
Emergency-Response Statement Get medical help or contact a Poison Control Center (1-800-222-1222) right away.
When Immediate Medical Help is Required Immediate medical attention is critical for adults as well as children, even if no signs or symptoms of overdose are immediately noticed.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose manifestations are an exaggeration of the drug's intended action, leading to severe fluid loss through diarrhea.
  • The primary serious risk is the potential development of severe dehydration and clinically significant electrolyte imbalances due to excessive fluid depletion.
  • Regulators mandate that professional help be sought immediately in all cases of suspected overdose.
  • Management for an overdose focuses on providing supportive care, specifically to address and replace lost fluids and electrolytes.

Connection to the Overall Overdose Profile: The regulatory profile strictly defines overdose by its physiological consequences—severe fluid and electrolyte loss resulting from excessive laxative effect. This potential for serious systemic complication dictates the non-negotiable emergency-seeking condition, which requires immediate contact with the Poison Control Center or a healthcare professional, as stated in the official governmental warnings.

Therapeutic Uses of Phillips Stool Softener

Main Uses of Phillips Stool Softener

Phillips Stool Softener is primarily utilized for the relief of occasional constipation. Unlike stimulant laxatives that induce bowel movements by irritating the intestinal lining, this product is classified as an emollient laxative. Its main function is to facilitate the mixing of water and fats into the stool, which helps to soften the waste material and make it easier to pass.

This softening effect is particularly useful in several clinical and personal contexts:

  • Prevention of Straining: It is frequently used by individuals who need to avoid straining during bowel movements, such as those recovering from surgery, individuals with heart conditions, or those with painful hemorrhoids.
  • Hard Stools: It is indicated for the management of stools that are dry, hard, or difficult to expel.
  • Gradual Relief: It provides a gentle approach to regularity, typically producing a bowel movement within 12 to 72 hours.

Benefits and Mechanism of Action

The primary benefit of Phillips Stool Softener is its gentle mechanism of action. Because it does not stimulate the nerves or muscles of the digestive tract directly, it is often preferred for those who experience cramping or urgency with other types of laxatives.

Softening and Hydration

The active ingredient works by reducing the surface tension of the stool. This allows the intestinal fluids to penetrate the fecal mass more effectively. The result is a more pliable stool, which reduces the physical discomfort associated with constipation.

Compatibility with Other Needs

Because this product focuses on stool consistency rather than transit speed, it can be an integrated part of a bowel management plan for those with chronic conditions that require soft stools to prevent secondary complications, such as anal fissures. It offers a predictable way to maintain comfort without the intensity often associated with more aggressive laxative options.

Regulatory References

  1. NIH MedlinePlus guidance on Stool Softeners

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Phillips Stool Softener

Classification Group
Populations for whom use is allowed Adults and children 12 years and over
Children 2 to under 12 years of age
Populations for whom use is contraindicated Patients presently taking mineral oil (unless directed by a doctor)
Patients with stomach pain, nausea, or vomiting
Patients with a known hypersensitivity to docusate sodium
Patients needing use for longer than 1 week (unless directed by a doctor)
Age-related eligibility rules Children under 2 years must consult a doctor before use
Condition-specific eligibility rules A doctor must be consulted if a sudden change in bowel habits persists over 2 weeks
Rectal bleeding or failure to have a bowel movement after use requires stopping use and consulting a doctor
Pregnancy and lactation eligibility status Pregnant or breast-feeding individuals must ask a health professional before use

Connection to the overall eligibility profile

Official regulatory documents define the eligibility profile by explicitly classifying populations who are permitted for standard use (adults and older children) and those who are prohibited (e.g., mineral oil users or patients with acute abdominal symptoms). The labeling establishes clear boundaries by requiring consultation for use in specific populations, such as children under 2 years of age, and those who are pregnant or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Docusate sodium (Phillips Stool Softener) is officially characterized by pharmacokinetic interactions that alter the systemic exposure of certain co-administered substances. This effect stems from docusate's surfactant properties, which can enhance the gastrointestinal absorption of other lipophilic agents, as documented in regulatory prescribing information.


Official Interaction Statements and Restrictions

Category Official Regulatory Statement Restriction
Co-administration The product is officially restricted for concurrent use with Mineral Oil (Liquid Paraffin). Co-administration is prohibited or strongly warned against unless medically directed.
Absorption Risk Docusate enhances the systemic absorption of substances like Mineral Oil, Danthran, and Phenolphthalein. Risk of increased exposure for the co-administered drug.
Dose Adjustment Docusate increases the absorption of Anthraquinone Derivatives. Requires the derivative to be taken in reduced doses if co-administered.
Timing Rule The official label includes a mandatory timing separation requirement. Should not be taken within 2 hours of another oral medication.

This interaction structure is driven by regulatory classification of these effects as clinically significant, necessitating explicit constraints on co-administration and dosage timing. The primary concern is the increased exposure of the interacting agent due to enhanced absorption.

Mechanism of Action

️ How Phillips Stool Softener Works: Mechanistic Action

Phillips Stool Softener operates through the active ingredient Docusate sodium, a pure anionic surfactant acting exclusively within the gastrointestinal lumen. Its primary mechanism is the reduction of fecal surface tension. This physicochemical interaction allows existing water and lipids to readily penetrate and emulsify within the dry, hydrophobic components of the fecal mass. This critical step results in an increase in the water content of the feces and a reduction in its viscosity.

Beyond this direct softening, the molecule interacts with the intestinal epithelial barrier, functioning as a mild permeability enhancer and secretagogue. This mucosal interaction may modulate local signaling pathways to promote the secretion of water and electrolytes into the colon's lumen. The resulting increase in intraluminal fluid volume complements the primary action by increasing the lubricity of the fecal material.

This mechanism is inherently slow-acting (requiring 1 to 3 days) due to its dependence on the gradual, mechanical saturation of the fecal mass. Notably, the molecule has no direct pro-motility action; it does not stimulate the colon's smooth muscle or nerves, ensuring the physiological response is solely dependent on the natural propulsive motility of the colon.

Dosage and Administration Information

How to Use Phillips Stool Softener

The usage of Phillips Stool Softener, which contains Docusate sodium, follows instructions detailing its administration, dosage, and duration of use. The medication is for the oral route of administration in available forms such as softgels, capsules (50 mg or 100 mg), and an oral liquid solution (50 mg/5 mL).


Official Dosing Regimens

For adults and children 12 years of age and older, the typical daily dose ranges from 100 mg to 300 mg. This total daily amount may be administered either as a single dose or divided into smaller, multiple doses throughout the day. The expected time frame for the onset of a bowel movement is generally within 12 to 72 hours following the first dose.


Administration Requirements

Proper use requires specific intake conditions for each form. Softgels and capsules are taken with a full glass (8 oz) of water. The liquid solution may be mixed with milk, fruit juice, or infant formula to improve palatability and facilitate ingestion.


Use Constraints and Pediatric Rules

Usage is limited to short-term administration for occasional constipation, and the medication is not intended for use longer than seven consecutive days unless directed by a health professional. Dosing for children 6 to under 12 years is typically 100 mg once daily. For children 2 to under 6 years, the dose for the liquid form is 25 mg to 50 mg, while use in children under 2 years requires consultation with a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Phillips Stool Softener


Evidence for use in Occasional Constipation

Research has examined the use of this type of stool softener in individuals who experience occasional constipation. Studies often take the form of short-term randomized trials, focusing on outcomes related to systemic or functional imbalance in the digestive tract. These trials monitored changes in bowel movement frequency and stool consistency, which are patient-reported outcomes describing perceived discomfort.

The findings describe patterns observed in the studies where participants reported outcomes describing episodic or acute changes, such as reported changes in bowel movement frequency and stool consistency measured during the study period. The data show patterns related to temporary physiological changes, but the findings were mixed regarding the magnitude of these reported changes across different research settings. The certainty remains low regarding how these short-term measurements translate to sustained changes in bowel function.

Studies related to Opioid-Induced Constipation

The active ingredient was evaluated in studies involving individuals who experience constipation associated with taking opioid medications. This research explores a condition often marked by functional limitations. The studies report how symptoms evolved in the observed populations, indicating that the use of this type of stool softener was observed to coincide with reported changes in stool consistency and frequency among some participants in these specific research scenarios. Follow-up durations were limited in many of these studies, meaning long-term effects are not fully established for this specific application.

What is still Uncertain about Phillips Stool Softener

A primary area of uncertainty is the lack of long-term data for continuous use, meaning long-term effects are not fully established. Additionally, evidence quality varies across studies, and findings were mixed regarding the magnitude of reported changes in stool characteristics. The data are limited for certain groups, including children, pregnant individuals, and those with certain complex medical histories. Comparative evidence is lacking to fully contextualize the observed patterns relative to other available study populations and research designs.

Key Studies & References How useful is docusate in patients at risk for constipation: a systematic review of the evidence in the chronically ill

Frequently Asked Questions (FAQ)

Common questions about Phillips Stool Softener (FAQ)


Q: Does Phillips Stool Softener cause stomach cramping?

A: Regulatory documents, including official product labels, list abdominal cramping as one of the commonly reported gastrointestinal adverse reactions associated with the active ingredient, Docusate sodium. These reactions are typically mild. Other common side effects include nausea and diarrhea.


Q: Does the medicine contain any common allergens like gluten or lactose?

A: Official labeling provides a complete list of inactive ingredients used in the product. Reviewing the full inactive ingredient list on the specific product packaging is suggested if you have a known sensitivity, as this information can vary by formulation and is not universally standardized across regulatory summaries.


Q: What should be done if the stool softener does not seem to be working?

A: Official directions state that if a patient fails to have a bowel movement after using the medicine, the product should be discontinued and a health professional consulted. This guidance is in place because the medication is generally expected to produce a bowel movement within 12 to 72 hours.


Q: Can this medication change the color or texture of stool?

A: The primary intended effect of the medication is to soften the stool by increasing its water content, which changes its consistency and texture. While the stool softener alone is not commonly listed as causing stool color changes, some official product labels for related combination laxatives may note that they can cause urine to turn reddish-brown.


Q: Is it possible to become dependent on Phillips Stool Softener?

A: Regulatory documents caution that the prolonged or excessive use of this type of laxative, such as using it for longer than seven days, is associated with safety concerns. These concerns include the potential for developing a dependency for bowel function or experiencing an electrolyte imbalance. Regulatory constraints specify that the product is intended for short-term administration only.


Q: What happens if I miss a dose of the stool softener?

A: Since this product is typically used for occasional relief, official guidance often notes that the missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should generally be skipped to avoid taking excess medicine.


Q: Are there any specific foods or drinks to avoid while taking it?

A: Official product labeling strictly restricts concurrent use with Mineral Oil (Liquid Paraffin) due to a serious interaction risk. No specific dietary foods are generally listed as being forbidden, but the liquid form is often noted to be mixable with drinks like milk or fruit juice to improve its taste.


Q: Do studies support the use of stool softeners for general constipation?

A: Research has examined the use of Docusate sodium for occasional constipation. While the medication is officially approved for this purpose, some authoritative sources have reported that evidence regarding its efficacy in general constipation compared to an inactive substance has been mixed across different studies.


Q: Why is hydration often mentioned as important when taking this medicine?

A: The active ingredient works by helping the stool absorb existing water and fat. For the softening action to be successful, there must be enough fluid in the digestive system. Therefore, administration instructions often include taking the softgels or capsules with a full glass of water to complement the medication's effect and support the relief of constipation.


Q: Is a prescription needed for Phillips Stool Softener?

A: No, Phillips Stool Softener is classified by regulatory authorities as an over-the-counter (OTC) preparation. It is available for purchase without a prescription for the relief of occasional constipation.


Q: Does the effectiveness of the stool softener decrease over time?

A: Official labeling restricts the use of the product to a seven-day maximum unless directed by a health professional. This time constraint is in place due to the risk of issues associated with prolonged reliance on the product, such as dependency and electrolyte imbalance.


Q: What are the signs that the stool softener is working as intended?

A: The primary purpose of the medication, as stated on the label, is to relieve occasional constipation by softening the stool. This results in the production of a bowel movement, which is generally expected to occur within 12 to 72 hours after the first dose.


Q: Is it normal to experience mild gas or bloating when first starting this medicine?

A: Product information associated with the active ingredient, Docusate, sometimes includes gas or bloating among the common, generally mild side effects reported. These effects often accompany other gastrointestinal reactions like abdominal discomfort or diarrhea.


Q: Is Phillips Stool Softener the same as the milk of magnesia product from Phillips?

A: No, these are different products. Phillips Stool Softener contains Docusate sodium, which is an emollient laxative (stool softener). Phillips' Milk of Magnesia contains magnesium hydroxide, which is classified as a saline laxative and an antacid.


Q: Can excessive use of a stool softener lead to dehydration?

A: Official product warnings state that prolonged or excessive use increases the risk of electrolyte imbalance. Diarrhea is also a listed side effect, and if it is severe or persistent, the resulting fluid loss can potentially contribute to dehydration.


Q: Does using this medicine affect the body's natural bowel function after stopping?

A: Regulatory documents caution against long-term use due to the risk of dependency. Authoritative analysis reports that because the product is a non-stimulant, it is generally considered to have a different risk profile regarding long-term functional effects compared to stimulant laxatives.


Q: Is there evidence for using stool softeners for conditions other than constipation?

A: Studies have examined the use of the active ingredient for specific situations, such as in patients with Opioid-Induced Constipation (OIC). The medication may also be used in scenarios where straining must be avoided, like following certain medical procedures or when hemorrhoids are present.


Q: Can taking this product help prevent hemorrhoids?

A: Authoritative health agency information notes that by softening the stool, the medicine makes bowel movements easier and helps to reduce straining. By reducing straining, the medication supports comfortable bowel movements, which is considered beneficial for individuals with or at risk of hemorrhoids or anal fissures.


Q: Does the consistency of the stool change once the medicine is stopped?

A: The medication's mechanism involves incorporating water into the fecal mass, which is a temporary effect. Since it does not permanently change the body's digestive function, it is indicated that the stool consistency may revert to its prior state once the medicine is stopped.


Q: Is there a known 'rebound' effect when stopping this medication?

A: Authoritative sources suggest that because this active ingredient is a non-stimulant, meaning it does not act on the nervous system, rebound effects or withdrawal constipation are not generally considered a general concern when stopping its use.


Q: Does taking the product at night vs. in the morning change its effect?

A: Official dosing regimens allow the total daily amount to be taken either as a single dose or in divided doses throughout the day. Since the onset of the desired effect is delayed (12 to 72 hours), the specific time of day the dose is taken does not critically alter the eventual softening effect.


Q: What are the common misuses of this type of medicine?

A: The most common misuse specifically cautioned against in regulatory documents is the prolonged use of the product, meaning using it for more than seven days without professional guidance. It is also contraindicated for use when symptoms like stomach pain, nausea, or vomiting are present.

How should Phillips Stool Softener be stored and disposed of?

Storage and Disposal Requirements

The docusate sodium formulation must be stored at controlled room temperature, typically 25 C (77 F), with permitted excursions between 15 C and 30 C. It is mandatory to protect the product from excessive heat (above 40 C), freezing, and excessive humidity to maintain stability.

Handling and Child Safety

The container must be kept tightly closed. For child safety, the medicine must be stored out of the reach of children at all times.

Official Disposal Rules

Unused or expired docusate sodium should be disposed of by taking it to an authorized drug take-back location or by using the household trash disposal method. This involves mixing the medication with an unappealing substance, placing it in a sealed container, and discarding it. It is explicitly advised not to flush the medicine down the toilet or empty it into drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Phillips Stool Softener found in:

A-Z Index: